NASDAQ:BOLD - Audentes Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$37.92 -0.42 (-1.10 %)
(As of 05/22/2018 04:00 PM ET)
Previous Close$38.34
Today's Range$36.66 - $38.69
52-Week Range$13.90 - $42.61
Volume713,800 shs
Average Volume448,983 shs
Market Capitalization$1.41 billion
P/E Ratio-11.15
Dividend YieldN/A
Beta1.22

About Audentes Therapeutics (NASDAQ:BOLD)

Audentes Therapeutics logoAudentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. The company was founded in 2012 and is headquartered in San Francisco, California.

Receive BOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for BOLD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BOLD
CUSIPN/A
Phone415-818-1001

Debt

Debt-to-Equity RatioN/A
Current Ratio20.44
Quick Ratio20.45

Price-To-Earnings

Trailing P/E Ratio-11.15
Forward P/E Ratio-11.46
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($5.38) per share
Price / Book-7.05

Profitability

EPS (Most Recent Fiscal Year)($3.40)
Net Income$-90,230,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-41.55%

Miscellaneous

Employees152
Outstanding Shares36,740,000

Audentes Therapeutics (NASDAQ:BOLD) Frequently Asked Questions

What is Audentes Therapeutics' stock symbol?

Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."

How were Audentes Therapeutics' earnings last quarter?

Audentes Therapeutics (NASDAQ:BOLD) issued its quarterly earnings data on Wednesday, May, 9th. The biotechnology company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.07. View Audentes Therapeutics' Earnings History.

When is Audentes Therapeutics' next earnings date?

Audentes Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Audentes Therapeutics.

What price target have analysts set for BOLD?

10 brokerages have issued 12-month price targets for Audentes Therapeutics' stock. Their predictions range from $23.00 to $56.00. On average, they expect Audentes Therapeutics' stock price to reach $37.25 in the next twelve months. View Analyst Ratings for Audentes Therapeutics.

What are Wall Street analysts saying about Audentes Therapeutics stock?

Here are some recent quotes from research analysts about Audentes Therapeutics stock:
  • 1. Mizuho analysts commented, "We came away very encouraged by the data which showed continued improvements in the first cohort of patients, as well as early positive data in the expansion cohort. We see a stronger probability of success for the AT-132 program and we therefore raise our price target from $26 to $38 to reflect the higher PoS. We maintain our Neutral rating as we believe the shares are fairly priced." (5/21/2018)
  • 2. Raymond James analysts commented, "We are maintaining our Market Perform rating on BOLD. Therapy (ASGCT) annual meeting, the company provided an update on the ongoing Phase I/II ASPIRO study of AT132 for X-linked myotubular myopathy (XLMTM). By comparing the results of the ASPIRO study and those of the INCEPTUS trial, in our opinion, the totality of the updated data continues to suggest that AT132 provides a significant benefit to patients suffering with XLMTM, which may lead to an accelerated regulatory pathway. That said, we remain cautiously optimistic about the commercial prospect of this product given rare nature of the disease being pursued." (5/17/2018)
  • 3. William Blair analysts commented, "We view the update as a positive and initial safety concerns as largely overblown, particularly when compared with the data from the INCEPTUS run-in study and noting that the majority were in a single patient who had previously experienced several pneumonia episodes, a tachycardic event in the run-in trial, and was on 24 hours of invasive ventilation at baseline." (5/17/2018)
  • 4. According to Zacks Investment Research, "Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company's product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California. " (3/13/2018)

Who are some of Audentes Therapeutics' key competitors?

Who are Audentes Therapeutics' key executives?

Audentes Therapeutics' management team includes the folowing people:
  • Mr. Matthew R. Patterson, Co-Founder, CEO, Pres & Director (Age 46)
  • Mr. Thomas P. Soloway, CFO and Sr. VP (Age 51)
  • Ms. Natalie C. Holles, Chief Operating Officer and Sr. VP (Age 45)
  • Dr. John T. Gray Ph.D., Chief Scientific Officer and Sr. VP (Age 55)
  • Ms. Dawn Blessing, VP of Corp. Devel.

When did Audentes Therapeutics IPO?

(BOLD) raised $75 million in an initial public offering on Wednesday, July 20th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Has Audentes Therapeutics been receiving favorable news coverage?

Media coverage about BOLD stock has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Audentes Therapeutics earned a news impact score of 0.14 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 46.83 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Audentes Therapeutics' major shareholders?

Audentes Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.34%), Sofinnova Ventures Inc (3.76%), Redmile Group LLC (3.56%), Rock Springs Capital Management LP (1.54%), Victory Capital Management Inc. (1.49%) and Lord Abbett & CO. LLC (0.91%). Company insiders that own Audentes Therapeutics stock include 5Am Partners Iii, Llc, David Nagler, James E Flynn, Louis G Lange, Mary Newman, Matthew R Patterson, Orbimed Advisors Llc, Suyash Prasad and Versant Ventures Iv, Llc. View Institutional Ownership Trends for Audentes Therapeutics.

Which major investors are selling Audentes Therapeutics stock?

BOLD stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Opaleye Management Inc. and JPMorgan Chase & Co.. Company insiders that have sold Audentes Therapeutics company stock in the last year include David Nagler, Louis G Lange, Mary Newman, Matthew R Patterson, Orbimed Advisors Llc and Suyash Prasad. View Insider Buying and Selling for Audentes Therapeutics.

Which major investors are buying Audentes Therapeutics stock?

BOLD stock was purchased by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc, BlackRock Inc., Victory Capital Management Inc., Redmile Group LLC, Foresite Capital Management III LLC, Wells Fargo & Company MN, Millennium Management LLC and Lord Abbett & CO. LLC. Company insiders that have bought Audentes Therapeutics stock in the last two years include 5Am Partners Iii, Llc, James E Flynn, Orbimed Advisors Llc and Versant Ventures Iv, Llc. View Insider Buying and Selling for Audentes Therapeutics.

How do I buy shares of Audentes Therapeutics?

Shares of BOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Audentes Therapeutics' stock price today?

One share of BOLD stock can currently be purchased for approximately $37.92.

How big of a company is Audentes Therapeutics?

Audentes Therapeutics has a market capitalization of $1.41 billion. The biotechnology company earns $-90,230,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Audentes Therapeutics employs 152 workers across the globe.

How can I contact Audentes Therapeutics?

Audentes Therapeutics' mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company can be reached via phone at 415-818-1001 or via email at [email protected]


MarketBeat Community Rating for Audentes Therapeutics (BOLD)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  151 (Vote Outperform)
Underperform Votes:  141 (Vote Underperform)
Total Votes:  292
MarketBeat's community ratings are surveys of what our community members think about Audentes Therapeutics and other stocks. Vote "Outperform" if you believe BOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Audentes Therapeutics (NASDAQ:BOLD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
10 Wall Street analysts have issued ratings and price targets for Audentes Therapeutics in the last 12 months. Their average twelve-month price target is $37.25, suggesting that the stock has a possible downside of 1.77%. The high price target for BOLD is $56.00 and the low price target for BOLD is $23.00. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.802.782.80
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $37.25$35.3750$35.3750$28.00
Price Target Upside: 1.77% downside2.39% downside7.85% upside8.78% upside

Audentes Therapeutics (NASDAQ:BOLD) Consensus Price Target History

Price Target History for Audentes Therapeutics (NASDAQ:BOLD)

Audentes Therapeutics (NASDAQ:BOLD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/21/2018MizuhoReiterated RatingNeutral ➝ Hold$38.00LowView Rating Details
5/17/2018Raymond JamesReiterated RatingHoldHighView Rating Details
5/17/2018HC WainwrightSet Price TargetBuy$40.00HighView Rating Details
5/17/2018William BlairReiterated RatingBuyHighView Rating Details
5/10/2018WedbushBoost Price TargetOutperform$49.00 ➝ $56.00HighView Rating Details
3/9/2018CowenReiterated RatingBuyLowView Rating Details
1/5/2018BMO Capital MarketsSet Price TargetBuy$44.00HighView Rating Details
11/15/2017Leerink SwannReiterated RatingOutperform$22.00 ➝ $29.00N/AView Rating Details
9/22/2017Bank of AmericaReiterated RatingBuy$23.00 ➝ $33.00LowView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$23.00LowView Rating Details
11/12/2016Piper Jaffray CompaniesSet Price TargetBuy$24.00N/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Audentes Therapeutics (NASDAQ:BOLD) Earnings History and Estimates Chart

Earnings by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Audentes Therapeutics (NASDAQ:BOLD) Earnings Estimates

2018 EPS Consensus Estimate: ($3.26)
2019 EPS Consensus Estimate: ($3.35)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.84)($0.78)($0.81)
Q2 20184($0.80)($0.76)($0.79)
Q3 20184($0.83)($0.78)($0.81)
Q4 20184($0.90)($0.82)($0.85)
Q1 20192($0.87)($0.73)($0.80)
Q2 20192($0.91)($0.78)($0.85)
Q3 20192($0.93)($0.80)($0.87)
Q4 20192($0.84)($0.83)($0.84)

Audentes Therapeutics (NASDAQ BOLD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2018($0.80)N/AView Earnings Details
5/9/2018Q1 2018($0.81)($0.74)ViewN/AView Earnings Details
3/8/2018Q4 2017($0.91)($0.82)ViewListenView Earnings Details
11/14/2017Q3 2017($0.88)($0.88)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.77)($0.87)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.92)($0.83)ViewN/AView Earnings Details
3/9/201712/31/2016($0.75)($0.91)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.66)($0.94)ViewN/AView Earnings Details
8/31/2016Q2 2016($1.35)($6.43)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Audentes Therapeutics (NASDAQ:BOLD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Audentes Therapeutics (NASDAQ BOLD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.60%
Institutional Ownership Percentage: 95.29%
Insider Trading History for Audentes Therapeutics (NASDAQ:BOLD)
Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Audentes Therapeutics (NASDAQ BOLD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/2/2018Matthew R PattersonCEOSell700$30.01$21,007.00700View SEC Filing  
3/29/2018Suyash PrasadVPSell7,800$30.03$234,234.007,800View SEC Filing  
3/26/2018Louis G LangeDirectorSell48,000$28.89$1,386,720.00414,231View SEC Filing  
3/26/2018Suyash PrasadVPSell1,900$30.00$57,000.001,900View SEC Filing  
3/15/2018Mary NewmanSVPSell10,000$30.36$303,600.004,076View SEC Filing  
3/12/2018Orbimed Advisors LlcMajor ShareholderSell156,431$34.97$5,470,392.07View SEC Filing  
3/8/2018Orbimed Advisors LlcMajor ShareholderSell58,428$34.06$1,990,057.68View SEC Filing  
3/6/2018Orbimed Advisors LlcMajor ShareholderSell433,210$35.11$15,210,003.10View SEC Filing  
3/2/2018Orbimed Advisors LlcMajor ShareholderSell421,638$35.17$14,829,008.46View SEC Filing  
12/22/2017Louis G LangeDirectorSell18,000$30.88$555,840.00View SEC Filing  
12/1/2017Suyash PrasadVPSell8,000$28.53$228,240.00View SEC Filing  
11/16/2017Mary NewmanSVPSell10,000$26.84$268,400.00View SEC Filing  
10/2/2017Matthew R PattersonCEOSell25,000$27.92$698,000.00View SEC Filing  
9/29/2017Louis G LangeDirectorSell11,000$28.35$311,850.00441,555View SEC Filing  
9/29/2017Orbimed Advisors LlcMajor ShareholderSell672,000$28.25$18,984,000.00View SEC Filing  
9/27/2017David NaglerSVPSell3,750$30.00$112,500.003,750View SEC Filing  
9/25/2017Louis G LangeDirectorSell18,000$28.32$509,760.00453,393View SEC Filing  
9/18/2017Matthew R PattersonCEOSell10,000$25.06$250,600.001,542View SEC Filing  
9/15/2017David NaglerSVPSell3,750$25.00$93,750.003,750View SEC Filing  
9/7/2017Orbimed Advisors LlcMajor ShareholderSell5,000$22.35$111,750.00View SEC Filing  
9/1/2017Suyash PrasadVPSell8,000$21.44$171,520.008,000View SEC Filing  
8/24/2017Mary NewmanSVPSell10,000$20.00$200,000.0010,000View SEC Filing  
7/13/2017Matthew R PattersonCEOSell15,000$20.00$300,000.00View SEC Filing  
7/12/2017Matthew R PattersonCEOSell2,850$20.00$57,000.00View SEC Filing  
6/26/2017Louis G LangeDirectorSell15,000$19.78$296,700.00470,799View SEC Filing  
4/24/20175Am Partners Iii, LlcInsiderBuy172,413$14.50$2,499,988.50View SEC Filing  
7/25/2016James E FlynnInsiderBuy400,000$15.00$6,000,000.00View SEC Filing  
7/25/2016Orbimed Advisors LlcDirectorBuy33,334$15.00$500,010.00View SEC Filing  
7/25/2016Versant Ventures Iv, LlcMajor ShareholderBuy35,000$15.00$525,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Audentes Therapeutics (NASDAQ BOLD) News Headlines

Source:
DateHeadline
Comparing Audentes Therapeutics (BOLD) and BioCryst Pharmaceuticals (BCRX)Comparing Audentes Therapeutics (BOLD) and BioCryst Pharmaceuticals (BCRX)
www.americanbankingnews.com - May 22 at 10:03 AM
Audentes Therapeutics (BOLD) Rating Reiterated by MizuhoAudentes Therapeutics (BOLD) Rating Reiterated by Mizuho
www.americanbankingnews.com - May 21 at 9:55 AM
EIGR Soars On Progeria Deal, BOLD Investors Emboldened, BDSIs Cash StrengthensEIGR Soars On Progeria Deal, BOLD Investors Emboldened, BDSI's Cash Strengthens
www.nasdaq.com - May 18 at 10:56 AM
Notable Thursday Option Activity: WFC, BOLD, AXTANotable Thursday Option Activity: WFC, BOLD, AXTA
www.nasdaq.com - May 17 at 4:17 PM
Audentes Therapeutics (BOLD) PT Raised to $40.00 at HC WainwrightAudentes Therapeutics (BOLD) PT Raised to $40.00 at HC Wainwright
www.americanbankingnews.com - May 17 at 3:27 PM
Audentes Therapeutics (BOLD) Receives Hold Rating from Raymond JamesAudentes Therapeutics (BOLD) Receives Hold Rating from Raymond James
www.americanbankingnews.com - May 17 at 2:51 PM
Audentes Therapeutics (BOLD) Buy Rating Reaffirmed at William BlairAudentes Therapeutics' (BOLD) Buy Rating Reaffirmed at William Blair
www.americanbankingnews.com - May 17 at 11:45 AM
Audentes reports positive results from study of AT132 in XLMTM; shares up 7%Audentes reports positive results from study of AT132 in XLMTM; shares up 7%
seekingalpha.com - May 16 at 4:07 PM
Audentes Therapeutics (BOLD) Announces Continuing Positive Data from First Dose Cohort of ASPIROAudentes Therapeutics (BOLD) Announces Continuing Positive Data from First Dose Cohort of ASPIRO
www.streetinsider.com - May 16 at 4:07 PM
Audentes Announces Continuing Positive Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular MyopathyAudentes Announces Continuing Positive Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy
finance.yahoo.com - May 16 at 4:07 PM
Audentes Therapeutics (BOLD) Receives Average Recommendation of "Buy" from BrokeragesAudentes Therapeutics (BOLD) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 16 at 1:24 AM
Q2 2018 Earnings Forecast for Audentes Therapeutics Issued By William Blair (BOLD)Q2 2018 Earnings Forecast for Audentes Therapeutics Issued By William Blair (BOLD)
www.americanbankingnews.com - May 14 at 2:38 AM
Equities Analysts Set Expectations for Audentes Therapeutics Q2 2018 Earnings (BOLD)Equities Analysts Set Expectations for Audentes Therapeutics' Q2 2018 Earnings (BOLD)
www.americanbankingnews.com - May 14 at 2:38 AM
Q2 2018 Earnings Forecast for Audentes Therapeutics Issued By Piper Jaffray (BOLD)Q2 2018 Earnings Forecast for Audentes Therapeutics Issued By Piper Jaffray (BOLD)
www.americanbankingnews.com - May 14 at 2:38 AM
Audentes Therapeutics: Key Program UpdatesAudentes Therapeutics: Key Program Updates
seekingalpha.com - May 12 at 10:37 AM
Audentes Therapeutics (BOLD) Given Hold Rating at Raymond JamesAudentes Therapeutics (BOLD) Given Hold Rating at Raymond James
www.americanbankingnews.com - May 11 at 7:49 PM
 Analysts Expect Audentes Therapeutics (BOLD) Will Announce Earnings of -$0.79 Per Share Analysts Expect Audentes Therapeutics (BOLD) Will Announce Earnings of -$0.79 Per Share
www.americanbankingnews.com - May 11 at 5:36 PM
Audentes Therapeutics (BOLD) Forecasted to Earn FY2020 Earnings of ($3.15) Per ShareAudentes Therapeutics (BOLD) Forecasted to Earn FY2020 Earnings of ($3.15) Per Share
www.americanbankingnews.com - May 11 at 11:47 AM
Edited Transcript of BOLD earnings conference call or presentation 9-May-18 8:30pm GMTEdited Transcript of BOLD earnings conference call or presentation 9-May-18 8:30pm GMT
finance.yahoo.com - May 11 at 10:55 AM
Audentes Therapeutics (BOLD) Given a $37.00 Price Target at HC WainwrightAudentes Therapeutics (BOLD) Given a $37.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 10 at 1:28 PM
Wedbush Reaffirms Outperform Rating for Audentes Therapeutics (BOLD)Wedbush Reaffirms Outperform Rating for Audentes Therapeutics (BOLD)
www.americanbankingnews.com - May 10 at 1:28 PM
Audentes Therapeutics beats by $0.06Audentes Therapeutics beats by $0.06
seekingalpha.com - May 10 at 10:06 AM
Audentes Therapeutics (BOLD) CEO Matt Patterson on Q1 2018 Results - Earnings Call TranscriptAudentes Therapeutics' (BOLD) CEO Matt Patterson on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 10:06 AM
Audentes Therapeutics: 1Q Earnings SnapshotAudentes Therapeutics: 1Q Earnings Snapshot
www.cnbc.com - May 10 at 10:06 AM
Audentes Therapeutics (BOLD) Issues  Earnings Results, Beats Estimates By $0.13 EPSAudentes Therapeutics (BOLD) Issues Earnings Results, Beats Estimates By $0.13 EPS
www.americanbankingnews.com - May 9 at 10:46 PM
What Should We Expect From Audentes Therapeutics Inc’s (NASDAQ:BOLD) Earnings In The Next Couple Of Years?What Should We Expect From Audentes Therapeutics Inc’s (NASDAQ:BOLD) Earnings In The Next Couple Of Years?
finance.yahoo.com - May 9 at 4:10 PM
Audentes Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate UpdateAudentes Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 9 at 4:10 PM
Audentes Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference 2018Audentes Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference 2018
finance.yahoo.com - May 9 at 9:54 AM
Audentes Therapeutics (BOLD) Names Natalie Holles President and COOAudentes Therapeutics (BOLD) Names Natalie Holles President and COO
www.streetinsider.com - May 8 at 9:46 AM
Audentes Therapeutics Announces the Promotion of Natalie Holles to President and Chief Operating OfficerAudentes Therapeutics Announces the Promotion of Natalie Holles to President and Chief Operating Officer
finance.yahoo.com - May 8 at 9:46 AM
HC Wainwright Analysts Give Audentes Therapeutics (BOLD) a $37.00 Price TargetHC Wainwright Analysts Give Audentes Therapeutics (BOLD) a $37.00 Price Target
www.americanbankingnews.com - May 2 at 12:00 PM
Audentes Therapeutics to Release First Quarter 2018 Financial Results and Provide Corporate Update on Wednesday, May 9, 2018Audentes Therapeutics to Release First Quarter 2018 Financial Results and Provide Corporate Update on Wednesday, May 9, 2018
finance.yahoo.com - May 2 at 9:46 AM
Audentes Therapeutics (BOLD) Set to Announce Quarterly Earnings on WednesdayAudentes Therapeutics (BOLD) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 2 at 3:14 AM
Audentes Therapeutics Announces Presentation of Data at the 21st Annual Meeting of the American Society of Gene and Cell TherapyAudentes Therapeutics Announces Presentation of Data at the 21st Annual Meeting of the American Society of Gene and Cell Therapy
finance.yahoo.com - April 30 at 4:07 PM
Intellia Therapeutics: An In Vivo AdvantageIntellia Therapeutics: An In Vivo Advantage
seekingalpha.com - April 27 at 4:09 PM
-$0.81 EPS Expected for Audentes Therapeutics (BOLD) This Quarter-$0.81 EPS Expected for Audentes Therapeutics (BOLD) This Quarter
www.americanbankingnews.com - April 24 at 8:08 AM
Comparing Audentes Therapeutics (BOLD) & Biogen (BIIB)Comparing Audentes Therapeutics (BOLD) & Biogen (BIIB)
www.americanbankingnews.com - April 11 at 1:17 PM
Audentes Therapeutics (BOLD) Downgraded to Sell at ValuEngineAudentes Therapeutics (BOLD) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - April 10 at 7:51 PM
First Week of BOLD November 16th Options TradingFirst Week of BOLD November 16th Options Trading
www.nasdaq.com - April 10 at 4:07 PM
Novartis takeout of AveXis stokes buying in gene therapy playersNovartis takeout of AveXis stokes buying in gene therapy players
seekingalpha.com - April 9 at 10:09 AM
Audentes Therapeutics (BOLD) Expected to Post Earnings of -$0.81 Per ShareAudentes Therapeutics (BOLD) Expected to Post Earnings of -$0.81 Per Share
www.americanbankingnews.com - April 7 at 9:55 AM
Audentes Therapeutics (BOLD) Coverage Initiated by Analysts at William BlairAudentes Therapeutics (BOLD) Coverage Initiated by Analysts at William Blair
www.americanbankingnews.com - April 6 at 10:54 PM
Audentes Therapeutics (BOLD) Raised to Hold at ValuEngineAudentes Therapeutics (BOLD) Raised to Hold at ValuEngine
www.americanbankingnews.com - April 5 at 2:14 PM
Audentes Therapeutics Inc (BOLD) CEO Matthew R. Patterson Sells 700 SharesAudentes Therapeutics Inc (BOLD) CEO Matthew R. Patterson Sells 700 Shares
www.americanbankingnews.com - April 4 at 11:37 PM
Audentes Therapeutics Inc (BOLD) SVP Sells $303,600.00 in StockAudentes Therapeutics Inc (BOLD) SVP Sells $303,600.00 in Stock
www.americanbankingnews.com - April 2 at 10:20 PM
Audentes Therapeutics Inc (BOLD) VP Sells $234,234.00 in StockAudentes Therapeutics Inc (BOLD) VP Sells $234,234.00 in Stock
www.americanbankingnews.com - March 29 at 10:46 PM
Insider Selling: Audentes Therapeutics Inc (BOLD) VP Sells 1,900 Shares of StockInsider Selling: Audentes Therapeutics Inc (BOLD) VP Sells 1,900 Shares of Stock
www.americanbankingnews.com - March 28 at 10:48 PM
Insider Selling: Audentes Therapeutics Inc (BOLD) Director Sells 48,000 Shares of StockInsider Selling: Audentes Therapeutics Inc (BOLD) Director Sells 48,000 Shares of Stock
www.americanbankingnews.com - March 28 at 10:31 PM
Audentes Therapeutics (BOLD) PT Set at $37.00 by HC WainwrightAudentes Therapeutics (BOLD) PT Set at $37.00 by HC Wainwright
www.americanbankingnews.com - March 28 at 8:42 PM
Audentes Therapeutics Inc (BOLD) Receives Average Recommendation of "Buy" from AnalystsAudentes Therapeutics Inc (BOLD) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 27 at 1:39 AM

SEC Filings

Audentes Therapeutics (NASDAQ:BOLD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Audentes Therapeutics (NASDAQ:BOLD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Audentes Therapeutics (NASDAQ BOLD) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.